valrubicin has been researched along with Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blum, RH; Frei, E; Garnick, MB; Henderson, IC; Israel, M; Panellos, GP | 1 |
| Blum, RH; Canellos, GP; Frei, E; Garnick, MB; Henderson, IC; Israel, M | 1 |
| Bodley, AL; Hsiang, YH; Israel, M; Kirschenbaum, S; Liu, LF; Potmesil, M; Seshadri, R; Silber, R; Sweatman, TW | 1 |
3 other study(ies) available for valrubicin and Neoplasms
| Article | Year |
|---|---|
Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Doxorubicin; Drug Evaluation; Drug Evaluation, Preclinical; Humans; Middle Aged; Neoplasms; Neoplasms, Experimental; Rabbits | 1981 |
Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog.
Topics: Doxorubicin; Drug Evaluation; Female; Humans; Male; Neoplasms | 1979 |
Metabolic activation of N-acylanthracyclines precedes their interaction with DNA topoisomerase II.
Topics: Animals; Biotransformation; Cell Line; DNA Topoisomerases, Type II; Doxorubicin; Drug Evaluation; Drug Evaluation, Preclinical; Humans; Mice; Mice, Inbred Strains; Neoplasms; Rats; Rats, Inbred Strains | 1987 |